Multiple Sclerosis Drugs Market
Multiple Sclerosis Drugs Market - Global Industry Assessment & Forecast
#
Pages:
147
Base Year:
2022
Dec - 2024
Format:
Report Code:
VMR-1859
Segments Covered
By
Drug Class Immunosuppressants, Immunomodulators, Interferons, Other Drug Classes
-
By
Route of Administration Oral, Injectable
-
By
Distribution Channel Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 25.90 Billion |
 Revenue 2030:
|
USD 34.36 Billion |
 Revenue CAGR
(2023 - 2030): |
3.60% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Multiple Sclerosis Drugs Market Segment Analysis
- Multiple Sclerosis Drugs Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Multiple Sclerosis Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Oral
- Injectable
- Multiple Sclerosis Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
-
North America Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
-
North America Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U.S.
- U.S. Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- U.S. Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- U.S. Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U.S. Multiple Sclerosis Drugs Market, by Drug Class
- Canada
- Canada Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Canada Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- Canada Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Canada Multiple Sclerosis Drugs Market, by Drug Class
-
Mexico
- Mexico Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Mexico Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- Mexico Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Mexico Multiple Sclerosis Drugs Market, by Drug Class
-
North America Multiple Sclerosis Drugs Market, by Drug Class
- Europe
-
Europe Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
-
Europe Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
-
Europe Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U. K.
- U.K. Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- U.K. Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- U.K. Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U.K. Multiple Sclerosis Drugs Market, by Drug Class
- France
- France Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- France Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- France Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- France Multiple Sclerosis Drugs Market, by Drug Class
-
Germany
- Germany Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Germany Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- Germany Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Germany Multiple Sclerosis Drugs Market, by Drug Class
-
Italy
- Italy Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Italy Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- Italy Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Italy Multiple Sclerosis Drugs Market, by Drug Class
-
Spain
- Spain Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Spain Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- Spain Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Spain Multiple Sclerosis Drugs Market, by Drug Class
-
Rest of Europe
- Rest of Europe Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Rest of Europe Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- Rest of Europe Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Rest of Europe Multiple Sclerosis Drugs Market, by Drug Class
-
Europe Multiple Sclerosis Drugs Market, by Drug Class
- Asia Pacific
-
Asia Pacific Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
-
Asia Pacific Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
-
Asia Pacific Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- China
- China Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- China Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- China Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- China Multiple Sclerosis Drugs Market, by Drug Class
- Japan
- Japan Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Japan Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- Japan Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Japan Multiple Sclerosis Drugs Market, by Drug Class
-
Germany
- Germany Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Germany Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- Germany Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Germany Multiple Sclerosis Drugs Market, by Drug Class
-
India
- India Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- India Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- India Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- India Multiple Sclerosis Drugs Market, by Drug Class
-
South Korea
- South Korea Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- South Korea Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- South Korea Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- South Korea Multiple Sclerosis Drugs Market, by Drug Class
-
South East Asia
- South East Asia Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- South East Asia Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- South East Asia Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- South East Asia Multiple Sclerosis Drugs Market, by Drug Class
-
Rest of Asia Pacific
- Rest of Asia Pacific Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Rest of Asia Pacific Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- Rest of Asia Pacific Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Rest of Asia Pacific Multiple Sclerosis Drugs Market, by Drug Class
-
Asia Pacific Multiple Sclerosis Drugs Market, by Drug Class
- Latin America
-
Latin America Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
-
Latin America Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
-
Latin America Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Brazil
- Brazil Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Brazil Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- Brazil Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Brazil Multiple Sclerosis Drugs Market, by Drug Class
- Argentina
- Argentina Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Argentina Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- Argentina Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Argentina Multiple Sclerosis Drugs Market, by Drug Class
-
Rest of Latin America
- Rest of Latin America Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Rest of Latin America Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- Rest of Latin America Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Rest of Latin America Multiple Sclerosis Drugs Market, by Drug Class
-
Latin America Multiple Sclerosis Drugs Market, by Drug Class
- Middle East & Africa
-
Middle East & Africa Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
-
Middle East & Africa Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
-
Middle East & Africa Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- GCC Countries
- GCC Countries Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- GCC Countries Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- GCC Countries Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- GCC Countries Multiple Sclerosis Drugs Market, by Drug Class
- South Africa
- South Africa Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- South Africa Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- South Africa Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- South Africa Multiple Sclerosis Drugs Market, by Drug Class
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Multiple Sclerosis Drugs Market, by Drug Class
- Immunosuppressants
- Immunomodulators
- Interferons
- Other Drug Classes
- Rest of Middle East & Africa Multiple Sclerosis Drugs Market, by Route of Administration
- Oral
- Injectable
- Rest of Middle East & Africa Multiple Sclerosis Drugs Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Rest of Middle East & Africa Multiple Sclerosis Drugs Market, by Drug Class
-
Middle East & Africa Multiple Sclerosis Drugs Market, by Drug Class
- North America
Vantage Market
Research | 10-Oct-2022
FAQ
Frequently Asked Question
What is the global demand for Multiple Sclerosis Drugs in terms of revenue?
-
The global Multiple Sclerosis Drugs valued at USD 25.90 Billion in 2022 and is expected to reach USD 34.36 Billion in 2030 growing at a CAGR of 3.60%.
Which are the prominent players in the market?
-
The prominent players in the market are Celgene Corporation, Acorda Therapeutics Inc., Biogen Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA), Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG., Sanofi, F. Hoffmann-La Roche Ltd..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 3.60% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Multiple Sclerosis Drugs include
- Significant R&D Investment by Market Players to Boost the Market
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Multiple Sclerosis Drugs in 2022.
